CN101574339A - β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 - Google Patents
β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 Download PDFInfo
- Publication number
- CN101574339A CN101574339A CNA2008100941226A CN200810094122A CN101574339A CN 101574339 A CN101574339 A CN 101574339A CN A2008100941226 A CNA2008100941226 A CN A2008100941226A CN 200810094122 A CN200810094122 A CN 200810094122A CN 101574339 A CN101574339 A CN 101574339A
- Authority
- CN
- China
- Prior art keywords
- methoxy
- phenyl
- chromen
- trihydroxy
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 22
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 18
- PPCHTBBOSVKORE-UHFFFAOYSA-N 3,5-dihydroxy-2-(4-methoxyphenyl)-8,8-dimethyl-9,10-dihydropyrano[2,3-h]chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C3OC(C)(C)CCC3=C2O1 PPCHTBBOSVKORE-UHFFFAOYSA-N 0.000 title abstract description 10
- 239000007924 injection Substances 0.000 claims abstract description 8
- 238000002347 injection Methods 0.000 claims abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 3
- TUUXBSASAQJECY-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 TUUXBSASAQJECY-UHFFFAOYSA-N 0.000 claims description 96
- 238000006297 dehydration reaction Methods 0.000 claims description 49
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 3
- 230000001055 chewing effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- -1 patch Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 18
- 206010008118 cerebral infarction Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 208000031225 myocardial ischemia Diseases 0.000 description 10
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 201000006474 Brain Ischemia Diseases 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 201000008247 brain infarction Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 3
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 3
- 210000003657 middle cerebral artery Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical group COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 101001005952 Rattus norvegicus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940079466 nimodipine 30 mg Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100941226A CN101574339B (zh) | 2008-05-05 | 2008-05-05 | β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100941226A CN101574339B (zh) | 2008-05-05 | 2008-05-05 | β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101574339A true CN101574339A (zh) | 2009-11-11 |
CN101574339B CN101574339B (zh) | 2011-06-01 |
Family
ID=41269502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100941226A Expired - Fee Related CN101574339B (zh) | 2008-05-05 | 2008-05-05 | β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101574339B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271903A (zh) * | 2013-05-21 | 2013-09-04 | 赵全成 | 淫羊藿素、环淫羊藿素及组合物的医药新用途 |
CN103989696A (zh) * | 2014-06-10 | 2014-08-20 | 遵义医学院 | 宝霍苷i在制备预防及治疗缺血性脑卒中药物中的应用 |
CN104592246A (zh) * | 2013-10-30 | 2015-05-06 | 周亚伟 | 一种黄酮类化合物及其制备方法和应用 |
CN105963293A (zh) * | 2016-05-30 | 2016-09-28 | 青岛云天生物技术有限公司 | 一种用于心肌梗死治疗的药物组合物及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1194716C (zh) * | 2001-12-24 | 2005-03-30 | 王隶书 | 一种以三七、淫羊藿为原料而制得的抗冠心病中成药 |
CN1813775A (zh) * | 2005-02-03 | 2006-08-09 | 周亚伟 | 淫羊藿苷在制备治疗冠心病药物中的应用 |
CN100441177C (zh) * | 2006-06-13 | 2008-12-10 | 中山大学 | 环淫羊藿甙元作为制备防治器官移植排斥反应药物的应用 |
-
2008
- 2008-05-05 CN CN2008100941226A patent/CN101574339B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271903A (zh) * | 2013-05-21 | 2013-09-04 | 赵全成 | 淫羊藿素、环淫羊藿素及组合物的医药新用途 |
CN104592246A (zh) * | 2013-10-30 | 2015-05-06 | 周亚伟 | 一种黄酮类化合物及其制备方法和应用 |
CN103989696A (zh) * | 2014-06-10 | 2014-08-20 | 遵义医学院 | 宝霍苷i在制备预防及治疗缺血性脑卒中药物中的应用 |
CN105963293A (zh) * | 2016-05-30 | 2016-09-28 | 青岛云天生物技术有限公司 | 一种用于心肌梗死治疗的药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101574339B (zh) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010513360A (ja) | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 | |
CN101278928B (zh) | 含左卡尼汀或其衍生物的药物组合物及其用途 | |
CN101574339B (zh) | β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 | |
CN106074493A (zh) | 一种大麻提取物在制备治疗痛风性关节炎药物中的应用 | |
CN106074465A (zh) | 大麻酚类化合物在制备治疗痛风性关节炎药物中的应用 | |
CN100486603C (zh) | 一种淫羊藿总黄酮环糊精或环糊精衍生物的包合物及其制剂和制备方法 | |
RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
CN108904808A (zh) | 一种治疗便秘的药物组合物及其应用 | |
CN101843627B (zh) | 二氢菲苷类化合物在制备防治心脑血管疾病药物中的应用 | |
CN1582159A (zh) | 增加了溶解度的黄烷醇木脂体制备物 | |
EP3263114A1 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
CN1679697A (zh) | 一种含有三七、瓜蒌皮、水蛭的治疗心血管疾病的中药制剂及其制备方法 | |
JP2020537689A (ja) | A−ノル−5αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
CN113876786B (zh) | 一种肝纤维化防治药物 | |
CN1762341A (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 | |
JP3247381B2 (ja) | 抗コレラトキシン剤 | |
CN101637466A (zh) | 淫羊藿素在制备防治心脑血管疾病药物中的应用 | |
CN101007014B (zh) | 一种复方葛根素制剂 | |
KR20010009653A (ko) | 성기능 장애를 위한 치료용 조성물 | |
CN103690524A (zh) | 淫羊藿素在制备防治脑血管疾病药物中的应用 | |
CN1853708A (zh) | 中药红豆蔻及其提取物的制药新用途 | |
CN101032534A (zh) | 救必应总皂苷的制备方法及应用 | |
CN113577090B (zh) | 牛蒡子苷在制备前列腺增生药物中的应用 | |
CN1537541A (zh) | 蒙脱石在制药中的应用 | |
CN107625887A (zh) | 包含肉苁蓉的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU LVKAI GROWTH INVESTMENT CENTER (LIMITED PAR Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150120 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100084 HAIDIAN, BEIJING TO: 215125 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150120 Address after: 215125 No. 456, Pratt & Whitney Road, Suzhou Industrial Park, Jiangsu, China Patentee after: Suzhou green growth investment center (L.P.) Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110601 |